Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron - Structure Therapeutics
Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron Structure Therapeutics This biotech is working on a GLP-1 pill that could be better than the Wegovy version MarketWatch Structure Therapeutics reports significant weight loss from mid-stage GLP-1 pill statnews.com Structure touts 16% weight loss for aleniglipron as 'highest efficacy' for an oral GLP-1 yet Fierce Biotech Structure Therapeutics reports more Phase 2 data for oral GLP-1 Endpoints News